Research Topics
| Alan Douglas TiceSummaryAffiliation: University of Hawaii Country: USA Publications
| Collaborators
|
Detail Information
Publications
Oritavancin: a new opportunity for outpatient therapy of serious infectionsAlan Tice
Infections Limited Hawaii, Honolulu, Hawaii 96814, USA
Clin Infect Dis 54:S239-43. 2012....- Access to care: the physician's perspectiveAlan Tice
Infections Limited Hawaii, Honolulu, Hawaii 96813, USA
Hawaii Med J 70:33-8. 2011..This was likely related to the more favorable impressions of the services, payments, and lower administrative burden offered by those companies compared with others... - Viral hepatitis in Hawai'i--differing perspectivesAlan D Tice
University of Hawai i John A Burns School of Medicine, Honolulu, HI, USA
Hawaii Med J 69:3-20. 2010.... - Quantitation of Staphylococcus aureus in seawater using CHROMagar SAAlan D Tice
Department of Medicine, John A Burns School of Medicine, University of Hawai i at Manoa, Honolulu, HI, USA
Hawaii Med J 69:8-12. 2010..A more rapid protocol, utilizing a 4-hour tube coagulase confirmatory test, enables a 48-hour turnaround time with a modest false negative rate of less than 10%... - Knowledge of severe acute respiratory syndrome among community physicians, nurses, and emergency medical respondersAlan Douglas Tice
Department of Medicine, University of Hawaii, John A Burns School of Medicine, Honolulu, Hawaii 96813 2427, USA
Prehosp Disaster Med 21:183-9. 2006..In order to determine the knowledge of these clinicians, a survey of their understanding of SARS and their use of educational resources was administered... - Outpatient parenteral antimicrobial therapy for central nervous system infectionsA D Tice
Infections Limited, P S, Tacoma, WA 98402, USA
Clin Infect Dis 29:1394-9. 1999..The antimicrobial used was changed in 13 cases (19%) because of an adverse effect or clinical failure. OPAT can be safe and effective for patients with CNS infections, but patients must be carefully selected and monitored closely... - Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelinesAlan D Tice
John A. Burns School of Medicine, University of Hawaii, Honolulu, HI 96813, USA
Clin Infect Dis 38:1651-72. 2004 - Ertapenem: a new opportunity for outpatient parenteral antimicrobial therapyAlan D Tice
John A Burns School of Medicine, University of Hawaii, Honolulu, HI, USA
J Antimicrob Chemother 53:ii83-6. 2004..Ertapenem should be added to the growing list of once-daily parenteral antibiotics that can be given to outpatients... - Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapyAlan D Tice
Infections Limited, P S, Tacoma, Washington, USA
Am J Med 114:723-8. 2003..To examine the effects of diabetes, vascular disease, age, and antimicrobial therapy on clinical outcomes, including amputation rates, in patients with osteomyelitis treated in the outpatient setting... - Risk factors and treatment outcomes in osteomyelitisAlan D Tice
Infections Limited, P S, Tacoma, WA, USA
J Antimicrob Chemother 51:1261-8. 2003..03). Treatment with ceftriaxone was as effective as the penicillinase-resistant penicillins and cefazolin... - Pharmacoeconomic considerations in the ambulatory use of parenteral cephalosporinsA D Tice
University of Washington, Seattle, USA
Drugs 59:29-35; discussion 47-9. 2000..In order to achieve cost savings, managed care will increasingly rely on home and outpatient therapy. This pressure will need to be counterbalanced by quality assurance programmes and outcomes measurements... - The use of outpatient parenteral antimicrobial therapy in the management of osteomyelitis: data from the Outpatient Parenteral Antimicrobial Therapy Outcomes RegistriesA Tice
University of Washington School of Medicine, Seattle, Wash, USA
Chemotherapy 47:5-16. 2001..Data collected by the OPAT Outcomes Registry confirms that osteomyelitis can be safely and effectively treated with intravenous antibiotics outside the hospital... - Cost perspectives for outpatient intravenous antimicrobial therapyAlan D Tice
Outpatient Parenteral Antibiotic Therapy OPAT, Outcomes Registry, Tacoma, Washington 98402, USA
Pharmacotherapy 22:63S-70S. 2002..We found that the cost of outpatient therapy was substantial, although nonuniform, across payer types. Alternative outpatient therapies associated with lower risks for adverse events and lower costs should be considered... - Clinical predictors of treatment failure for diabetic foot infections: data from a prospective trialBenjamin A Lipsky
Veterans Affairs Puget Sound Health Care System, University of Washington School of Medicine, Seattle, WA 98108 1597, USA
Int Wound J 4:30-8. 2007..Increased white blood cell count and severe UT wound grade at baseline, but not other features, were significant independent and additive risk factors for clinical failure in patients treated for a diabetic foot infection... - Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infectionsAlan D Tice
John A Burns School of Medicine, University of Hawaii, Honolulu, USA
Am J Health Syst Pharm 64:1080-6. 2007..To evaluate potential cost savings, trial data were used to determine the clinical outcomes for i.v. ertapenem given once daily and i.v. piperacillin-tazobactam given every six hours daily in treating diabetic foot infections... - Survey of methicillin-resistant Staphylococcus aureus (MRSA) carriage in healthy college students, Hawai'iJennifer E Morita
Department of Microbiology, Kapi olani Community College, Honolulu, HI 96816, USA
Hawaii Med J 66:213-5. 2007..Additional testing of a larger group of healthy individuals would be beneficial in assessing factors associated with CA-MRSA and Methicillin-susceptible Staphylococcus aureus (MSSA) carriage in Hawai'i... - Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trialBenjamin A Lipsky
University of Washington School of Medicine and Veterans Affairs Puget Sound Health Care System S 111 GIMC, 1660 S Columbian Way, Seattle, WA 98108, USA
Lancet 366:1695-703. 2005..Our aim was to assess the efficacy and safety of ertapenem versus piperacillin/tazobactam for foot infections... - Bloodborne pathogen exposure and recommendations for managementAlan D Tice
Department of Internal Medicine, John A Burns School of Medicine, University of Hawaii, USA
J Infus Nurs 25:S5-9. 2002..This article will focus on those agents as they pose the greatest known threats and offer the potential for intervention...